Spectrum Pharmaceuticals
Top View
- A First-In-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) with Selected Advanced Solid Tumors (ENGAGE-1)
- SPECTRUM PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Its Charter) ______
- Expert Connect All Relationships Are Considered Compensated
- Faculty Disclosure
- Mark H. Izraelewicz Partner
- The ASCO Post Editor Conflict of Interest Disclosures
- 02/04/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:10:22 Report Id 2794D051 Page: 01
- 2794D051numericlist May 2015.Xlsx
- Medicaid System (Mmis) Illinois Department of Run Date: 02/10/2015 Provider Subsystem Healthcare and Family Services Run Time: 20:51:09 Report Id 2794D052 Page: 01
- 2020 Annual Meeting Scientific Program Committee All Relationships Are Considered Compensated
- Spectrum Pharmaceuticals Appoints Lee F. Allen, M.D., Ph.D., Industry Veteran, As Chief Medical Officer
- U.S. Pharmaceutical/Biotech Industry Update
- COVID-19 and Cancer DISCLOSURE of FINANCIAL RELATIONSHIPS
- Rebateable Manufacturers
- Numeric Complete List of Pharmaceutical Labelers with Signed Rebate Agreements in Effect As of 10/01/2015
- Company Description
- Ligand's Partner Spectrum Pharmaceuticals Reports
- The Bottom 99